SAN DIEGO, Nov. 24, 2015 /PRNewswire/ -- Profil Institute for Clinical Research, a clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today the appointment of Meryl Wiernik as Senior Director of Clinical Operations.
Wiernik joins Profil Institute with more than 25 years of experience in clinical operations and global outsourcing management for the CRO and biopharmaceutical industry. In this new management position, Wiernik will lead the strategic expansion of Profil Institute’s CRO multi-center management services.
“Meryl has an outstanding track record in senior management roles within the CRO and biopharma industry. Her expertise will be highly impactful as we continue to expand our CRO services while maintaining our science driven, therapeutically focused approach,” said Dr. Linda Morrow, Profil Institute COO.
“Profil Institute has earned an outstanding reputation in the industry for its metabolism focus and scientific expertise. I’m excited to join this highly respected clinical operations team and to be a part of the strategic growth of their CRO services for biopharmaceutical clients globally,” said Wiernik. “I look forward to building upon the success the company has achieved to date by further expanding its multi-center management services.”
Wiernik is a highly accomplished leader with an extensive track record in developing and executing operational strategies within CRO and biopharmaceutical settings. She was most recently a consultant to the biopharma industry in areas of operations, quality assurance, and vendor management. Prior to that, she was the Vice President of Quality Assurance and Business Excellence for SynteractHCR, Inc., where she oversaw the integration process of global clinical trial conduct for Synteract and Harrison Clinical Research. Wiernik also served in leadership roles for global outsourcing at Teva Pharmaceuticals, Bristol Myers Squibb (BMS) and Amgen. During her 19 year tenure at BMS, she was instrumental in the conceptualization and implementation of the BMS Clinical Laboratory in support of its phase I unit as well as multi-site phase II-IV trials. Wiernik also served in leadership roles for business systems and operations at LabCorp Clinical Trials and Quest Diagnostics.
About Profil Institute for Clinical Research, Inc.
Profil Institute is an early engagement clinical research organization (CRO) exclusively focused on metabolic diseases, including diabetes, obesity and NAFLD/NASH. The company is recognized globally for its scientific expertise, expanded scope of research methodologies, and experience with every clinically relevant drug class in diabetes. Profil Institute provides a full scope of CRO services from consulting for strategic clinical development and regulatory planning through design and completion of complex clinical trials, including the reporting and publication of final study results.
Profil Institute has completed more than 230 clinical trials focused on metabolism, including diabetes, obesity and NAFLD/NASH. Profil Institute is leveraging that deep expertise in metabolic disease to become the leading CRO pursuing solutions for the unmet medical needs of NAFLD/NASH patients.
Profil Institute’s expertise and experience encompasses small and large molecule therapies, biologics and biosimilars through all routes of administration, as well as devices. The company’s clients range from large pharma and drug discovery companies to small virtual companies throughout the Americas, Europe and Asia.
Profil Institute is also widely recognized as an innovator of methodologies, including its Automated Glucose Clamp technology, and for driving new, higher standards in metabolic clinical research through collaborative science with key academic and industry partners. For more information, please visit www.profilinstitute.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/profil-institute-appoints-meryl-wiernik-as-senior-director-of-clinical-operations-300183711.html
SOURCE Profil Institute for Clinical Research, Inc.
